Katia E. Sutyak et al. detraction from its commercial applicability. Therefore, subtilosin’s spermicidal activity, combined with its overall safety to both human tissues and healthy human microbiota, make it a highly recommendable compound for inclusion in topical BV treatments and human contraceptive products. To facilitate the process of its incorporation into contraceptive treatments, additional analysis will be done to determine the reversibility of damage done to the spermatozoa, as well as a time course assay to further elucidate the exact changes eﬀected by subtilosin. ACKNOWLEDGMENTS This research was sponsored by NIH grant “Natural antimicrobials against bacterial vaginosis” NCCAM NIH R21AT002897-01. The authors thank Dr. Ayehunie at Mat- Tek Corporation for kind assistance and guidance. REFERENCES [1] K. Babasaki, T. Takao, Y. Shimonishi, and K. Kurahashi, “Subtilosin A, a new antibiotic peptide produced by Bacillus subtilis 168: isolation, structural analysis, and biogenesis,” The Journal of Biochemistry, vol. 98, no. 3, pp. 585–603, 1985. [2] K. E. Sutyak, R. E. Wirawan, A. A. Aroutcheva, and M. L. Chikindas, “Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens,” Journal of Applied Microbiology, vol. 104, no. 4, pp. 1067–1074, 2008. [3] K. E. Kawulka, T. Sprules, C. M. Diaper, et al., “Structure of subtilosin A, a cyclic antimicrobial peptide from Bacillus subtilis with unusual sulfur to α-carbon cross-links: formation and reduction of α-thio-α-amino acid derivatives,” Biochem- istry, vol. 43, no. 12, pp. 3385–3395, 2004. [4] J. E. Allsworth and J. F. Peipert, “Prevalence of bacterial vagi- nosis: 2001–2004 National Health and Nutrition Examination Survey data,” Obstetrics & Gynecology, vol. 109, no. 1, pp. 114– 120, 2007. [5] M. E. Falagas, G. I. Betsi, and S. Athanasiou, “Probiotics for the treatment of women with bacterial vaginosis,” Clinical Microbiology and Infection, vol. 13, no. 7, pp. 657–664, 2007. [6] L. Lin, J. Song, N. Kimber, et al., “The role of bacterial vagi- nosis in infection after major gynecologic surgery,” Infectious Diseases in Obstetrics and Gynecology, vol. 7, no. 3, pp. 169– 174, 1999. [7] R. S. Gibbs, “Asymptomatic bacterial vaginosis: is it time to treat?” American Journal of Obstetrics and Gynecology, vol. 196, no. 6, pp. 495–496, 2007. [8] S. L. Hillier, R. P. Nugent, D. A. Eschenbach, et al., “Association between bacterial vaginosis and preterm delivery of a low- birth-weight infant,” The New England Journal of Medicine, vol. 333, no. 26, pp. 1737–1742, 1995. [9] R. B. Ness, G. Trautmann, H. E. Richter, et al., “Eﬀectiveness of treatment strategies of some women with pelvic inﬂammatory disease: a randomized trial,” Obstetrics & Gynecology, vol. 106, no. 3, pp. 573–580, 2005. [10] M. V. Pararas, C. L. Skevaki, and D. A. Kafetzis, “Preterm birth due to maternal infection: causative pathogens and modes of prevention,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 25, no. 9, pp. 562–569, 2006. [11] J. A. Svare, H. Schmidt, B. B. Hansen, and G. Lose, “Bacterial vaginosis in a cohort of Danish pregnant women: prevalence 5 and relationship with preterm delivery, low birthweight and perinatal infections,” BJOG, vol. 113, no. 12, pp. 1419–1425, 2006. [12] N. Sewankambo, R. H. Gray, M. J. Wawer, et al., “HIV-1 infection associated with abnormal vaginal ﬂora morphology and bacterial vaginosis,” The Lancet, vol. 350, no. 9077, pp. 546–550, 1997. [13] T. E. Taha, D. R. Hoover, G. A. Dallabetta, et al., “Bacterial vaginosis and disturbances of vaginal ﬂora: association with increased acquisition of HIV,” AIDS, vol. 12, no. 13, pp. 1699– 1706, 1998. [14] P. Moodley, C. Connolly, and A. W. Sturm, “Interrelationships among human immunodeﬁciency virus type 1 infection, bac- terial vaginosis, trichomoniasis, and the presence of yeasts,” The Journal of Infectious Diseases, vol. 185, no. 1, pp. 69–73, 2002. [15] T. L. Cherpes, L. A. Meyn, M. A. Krohn, J. G. Lurie, and S. L. Hillier, “Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis,” Clinical Infectious Diseases, vol. 37, no. 3, pp. 319–325, 2003. [16] R. Kaul, N. J. Nagelkerke, J. Kimani, et al., “Prevalent herpes simplex virus type 2 infection is associated with altered vaginal ﬂora and an increased susceptibility to multiple sexually transmitted infections,” The Journal of Infectious Diseases, vol. 196, no. 11, pp. 1692–1697, 2007. [17] K. A. Workowski, W. C. Levine, and J. N. Wasserheit, “U.S. Centers for Disease Control and Prevention guidelines for the treatment of sexually transmitted diseases: an opportunity to unify clinical and public health practice,” Annals of Internal Medicine, vol. 137, no. 4, pp. 255–262, 2002. [18] R. M. Bannatyne and A. M. Smith, “Recurrent bacterial vagi- nosis and metronidazole resistance in Gardnerella vaginalis,” Sexually Transmitted Infections, vol. 74, no. 6, pp. 455–456, 1998. [19] M. M. Lubbe, P. L. Botha, and L. J. Chalkley, “Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 18, no. 1, pp. 46–54, 1999. [20] A. Liebetrau, A. C. Rodloﬀ, J. Behra-Miellet, and L. Dubreuil, “In vitro activities of a new des-ﬂuoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 11, pp. 3667–3671, 2003. [21] M. Maqueda, M. Sa´nchez-Hidalgo, M. Ferna´ndez, M. Mon- talba´n-Lo´ pez, E. Valdivia, and M. Mart´ınez-Bueno, “Genetic features of circular bacteriocins produced by Gram-positive bacteria,” FEMS Microbiology Reviews, vol. 32, no. 1, pp. 2–22, 2008. [22] C. van Kraaij, W. M. de Vos, R. J. Siezen, and O. P. Kuipers, “Lantibiotics: biosynthesis, mode of action and applications,” Natural Product Reports, vol. 16, no. 5, pp. 575–587, 1999. [23] T. R. Klaenhammer, “Genetics of bacteriocins produced by lactic acid bacteria,” FEMS Microbiology Reviews, vol. 12, no. 1–3, pp. 39–85, 1993. [24] C. Aranha, S. Gupta, and K. V. R. Reddy, “Contraceptive eﬃcacy of antimicrobial peptide Nisin: in vitro and in vivo studies,” Contraception, vol. 69, no. 4, pp. 333–338, 2004. [25] K. V. R. Reddy, C. Aranha, S. M. Gupta, and R. D. Yedery, “Evaluation of antimicrobial peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo studies,” Reproduction, vol. 128, no. 1, pp. 117–126, 2004. [26] L. Silkin, S. Hamza, S. Kaufman, S. L. Cobb, and J. C. Vederas, “Spermicidal bacteriocins: lacticin 3147 and subtilosin A,”